INSIGHTS ON ENTERPRISE SOLUTIONS
-
![Scientists in lab-GettyImages-1441665026]( "Bispecific Antibodies Unleashed")
Bispecific Antibodies UnleashedExplore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
![GettyImages-1437855768-lipid-nanoparticle-lnp-mrna vaccine]( "The Current And Future Value Of mRNA Vaccines And Therapeutics")
The Current And Future Value Of mRNA Vaccines And TherapeuticsDiscover how decades of research have propelled mRNA technology to the forefront of therapeutic development and learn how our expertise is advancing mRNA drug development.
-
![GettyImages-1133973085-monoclonal-antibody]( "Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs")
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbsDiscover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.
-
![iStock-1183376856-mice-mouse-study]( "Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody Discovery")
Leveraging The Immunological Diversity Of The Pentamice® Platform For Covid-19 Antibody DiscoveryConsider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
Designing Drug Substance Processes for Fill-Finish Compatibility2/4/2026
Integrated KBI and Argonaut solutions streamline drug substance to fill-finish transitions, resolving quality challenges, reducing delays, and accelerating timelines through coordinated processes and practical strategies.
-
The Value Of Engaging A Single CDMO For Comprehensive Biologics Services2/4/2026
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Protein Manufacturing Utilizing A Titerless Baculovirus Platform2/4/2026
Explore how an innovative titerless baculovirus platform accelerates protein manufacturing with enhanced scalability, reproducibility, and long-term virus stability for cutting-edge biologics production.
-
Bora Pharmaceuticals Capabilities Update January 2026: Fill/ Finish2/4/2026
Bora Pharmaceuticals expands global CDMO capabilities with new sterile fill/finish investments, supporting complex molecules and biologics through robust tech transfer, commercialization expertise, and integrated cGMP manufacturing solutions.
ENTERPRISE SOLUTIONS
-
![genetic research, biotechnology, molecular biology, innovation, healthcare solutions-GettyImages-2234236209]( "Biologics Discovery Capabilities")
Accelerate your biologics program with an integrated discovery‑to‑development partner built to deliver high‑quality candidates with speed and scientific rigor.
-
![GettyImages-1002000796-lab-research-scientist-development]( "Antibody Discovery & Engineering Services")
The Curia Antibody Center offers a comprehensive suite of services for researchers seeking the discovery and engineering of potent and functional antibodies.
-
![GettyImages-1187680243-biological-indicator-sterilization]( "Sterile Drug Product")
Accelerate sterile injectable development with expert support, advanced facilities, and tailored solutions for complex APIs — from formulation through commercialization across small molecules and biologics.
-
![GettyImages-1067806062-scientist-lab-vaccine-vial]( "Made For What's Next In Drug Delivery")
A global partner offering prefillable drug‑delivery systems, manufacturing expertise, and integrated services that accelerate development, secure supply, and support therapies across multiple areas.
-
![GettyImages-2167502114 bispecific antibodies]( "Every Detail. Built Around You.")
A U.S.‑based bio manufacturing campus offering end‑to‑end biologics and bioconjugation support with expert teams, scalable capacity, regulatory experience, and flexible solutions from early phase to commercial.
